

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

OVERSEAS REGULATORY ANNOUNCEMENT RESULTS OF A SUBSIDIARY

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Sichuan Rekind Medtec., Inc. (also known as Sichuan Ruijian Medical Technology Co. Ltd.) (四川睿健醫療科技股份有限公司) (NEEQ stock code: 874652) (“**Sichuan Ruijian Medical**”), a non-wholly owned subsidiary of PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), has announced its audited financial results for the nine months ended September 30, 2024 on the designated disclosure platform of the National Equities Exchange and Quotation System (“**NEEQS**”) (www.neeq.com.cn). The financial statements of Sichuan Ruijian Medical have been prepared in conformity with China Accounting Standards for Business Enterprises.

A summary of the financial results of Sichuan Ruijian Medical for the nine months ended September 30, 2024 is provided below.

INCOME STATEMENT

	For the nine months ended September 30, 2024 (RMB'000) (audited)
Revenue	341,698
Profit before tax	110,445
Income tax	(18,166)
Profit for the period	92,279
Profit attributable to the shareholders of Sichuan Ruijian Medical	92,627

BALANCE SHEET

As of
September 30, 2024
(RMB'000)
(audited)

Total Assets	888,759
Total Liabilities	69,865
Total Equity	818,894

GENERAL INFORMATION

The Company is an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011. The principal business activity of the Company is investment holding. The Group is principally engaged in the R&D, manufacturing and sales of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterial and human tissue repair alternative products in the People's Republic of China (the "PRC").

Sichuan Ruijian Medical is a joint stock limited liability company established in the PRC on August 6, 2013, the shares of which are quoted on the NEEQS (NEEQ stock code: 874652). Sichuan Ruijian Medical is a medical device company, principally engaged in the R&D, manufacturing and sales of medical device for blood purification.

Shareholders of the Company should note that the above audited results pertain only to Sichuan Ruijian Medical. The audited results will be consolidated in the accounts of the Company after adjustments in accordance with all applicable Hong Kong Financial Reporting Standards. Public investors and shareholders of the Company should exercise caution when dealing in its securities.

By order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, January 27, 2025

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.